XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 33.03

-4.7%

3:48 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Nikole Wollerstein	1/2/2011 1:45:08 PM
	Read Replies (1) of 17367

Gevokizumab (Xoma 052) Review Interleukin-1ß humanized monoclonal antibody for diabetes and immuno-inflammatory diseases The inflammatory cytokine IL-1ß has an essential role in the innate immune inflammatory response. High levels of IL-1ß have been implicated in the development of many diseases, including type 1 and 2 diabetes (T1D and T2D), rheumatoid arthritis (RA) and cardiovascular disease. ... XOMA is developing gevokizumab (XOMA-052), an IgG2 humanized mAb against human IL-1ß, for the potential treatment of these diseases. Gevokizumab has a high affinity for IL-1ß in the fentomolar range and a long half life of 23 days, which may allow for once-monthly dosing. Data from preclinical studies and clinical trials suggest that gevokizumab is an effective and well-tolerated treatment for the indicated diseases. Phase II clinical trials were ongoing in patients with T1D, T2D and RA, with the T2D trials assessing key cardiovascular markers. Following promising data from a pilot Phase I trial, XOMA was also planning a phase III trial of gevokizumab for the potential treatment of uveitis in patients with the vasculitic inflammatory disorder Behçet's disease and the autoinflammatory conditions familial cold autoinflammatory syndrome and Muckle-Wells syndrome. The fortunes of Xoma may be revived by the success of Gevokizumab in passing primary end point of efficacy ... knol.google.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next